uniQure N.V. (QURE)

4,5300 -0,0100 (-0,22%) Börsenschluss: 04:00PM EDT

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 480

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Matthew Craig Kapusta	CEO & Executive Director	1,02M	N/A	1972
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	575,46k	N/A	1973
Mr. Pierre Caloz	Chief Operating Officer	882,59k	N/A	1973
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer	732,17k	N/A	1968
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary	635,56k	N/A	1962
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/A	N/A	N/A
Dr. Tamara Tugal Ph.D., MBA	Business Development Director	N/A	N/A	N/A
Ms. Carla Poulson	Interim Chief People and Culture Officer	N/A	N/A	N/A
Ms. Maria E. Cantor	Chief Corporate Affairs Officer	491,12k	N/A	1968
Dr. Amin Abujoub Ph.D.	Chief Quality Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.s ISS Governance QualityScore, Stand 1. April 2024, lautet 2. Die grundlegenden Scores sind Audit: 5, Vorstand: 3, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.